The FLAURA study also reported osimertinib as offering both better PFS and Overall Survival (OS) when compared with first-generation EGFR-TKIs treatments for NSCLC patients with EGFR mutation in a first-line setting11,12. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.